Role of vitamin D in blood pressure homeostasis

American Journal of Therapeutics

Volumn 17, Issue 6, 2010, Pages

  Feneis, Jennifer F ^a   Arora, Rohit R ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

blood pressure; hypertension; review; vitamin D

Indexed keywords

25 HYDROXYVITAMIN D;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; HUMAN; HYPERTENSION; MEDLINE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; VITAMIN BLOOD LEVEL; VITAMIN INTAKE;

BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HOMEOSTASIS; HUMANS; HYPERTENSION; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 78649667906     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181d16999     Document Type: Article

References (38)

1. Food and Nutrition Board. Institute of Medicine. Dietary Reference Intakes for Calcium, Magnesium, Phosphorus, Vitamin D, and Fluoride. Washington, DC National Academy Press; 1997.
2. Snijder MB, van Dam RM, Visser M, et al. Adiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and women. J Clin Endocrinol Metab. 2005;90:4119-4123.
3. Wortsman J, Matsuoka LY, Chen TC, et al. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr. 2000;72:690-693.
4. Alemzadeh R, Kichler J, Babar G, et al. Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism. 2008;57:183-191.
5. Plotnikoff GA, Quigley JM. Prevalence of severe hypovitaminosis D in patients with persistent, non-specific musculoskeletal pain. Mayo Clin Proc. 2003;78: 1463-1470.
6. Chiu KC, Chu A, Go VLW, et al. Hypovitaminosis D is associated with insulin resistance and ß cell dysfunction. Am J Clin Nutr. 2004;79:820-825.
7. Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005;10:94-111.
8. Grant WB. An estimate of premature cancer mortality in the US due to inadequate doses of solar ultraviolet-B radiation. Cancer. 2002;94:1867-1875.
9. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: regulation of target gene expression. J Cell Biochem. 2003;88:363-371. (Pubitemid 36119910)
10. Lappe JM, Travers-Gustafson D, Davies KM, et al. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85: 1586-1591.
11. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81:353-373.
12. Kim DH, Sabour S, Sagar UN, et al. Prevalence of hypovitaminosis D in cardiovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol. 2008;102:1540-1544.
13. Melamed ML, Michos ED, Post W, et al. 25-Hydroxyvi-tamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008;168:1629-1637.
14. Giovannucci E, Liu Y, Hollis BW, et al. 25-Hydroxyvita-min D and risk of myocardial infarction in men. A prospective study. Arch Intern Med. 2008;168:1174-1180.
15. Wang L, Manson JE, Buring JE, et al. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hyper-tension. 2008;51:1073-1079.
16. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardio-vascular disease. Am J Clin Nutr. 2004;80:S1678-S1688.
17. Wu-Wong JR. Potential for vitamin D receptor agonists in the treatment of cardiovascular disease. Br J Pharmacol. 2009;158:395-412.
18. Harris SS. Vitamin D and African Americans. J Nutr. 2006; 136:1126-1129.
19. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension. 1997; 30:150-156.
20. Martins D, Wolf M, Pan D, et al. Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States. Data from the third National Health and Nutrition Examination Survey. Arch Intern Med. 2007;167:1159-1165.
21. Judd SE, Nanes MS, Ziegler TR, et al. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 2008;87:136-141.
22. Forman JP, Curhan GC, Taylor EN Plasma 25-hydrox-yvitamin D levels and risk of incident hypertension among young women. Hypertension. 2008;52:828-832.
23. Liu S, Song Y, Ford ES, et al. Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older US women. Diabetes Care. 2005;28: 2926-2932. (Pubitemid 43942926)
24. Joffres MR, Reed DM, Yano K. Relationship of magne-sium intake and other dietary factors to blood pressure: the Honolulu Heart Study. Am J Clin Nutr. 1987;45: 469-475.
25. Sowers MFR, Wallace RB, Lemke JH. The association of intakes of vitamin D and calcium with blood pressure among women. Am J Clin Nutr. 1985;42:135-142.
26. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr. 2009;89:1321-1327.
27. Sugden JA, Davies JI, Witham MD, et al. Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med. 2008;25:320-325.
28. Schleithoff SS, Zittermann A, Tenderich G, et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr. 2006;83:754-759.
29. 3 and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001;86:1633-1637.
30. 3 supplementation on cardiovascular risk factors in elderly adults. Eur J Clin Nutr. 1995;49:640-646.
31. Krause R, Buhring M, Hopfenmuller W, et al. Ultraviolet B and blood pressure. Lancet. 1998;352:709-710.
32. Lind L, Lithell H, Skarfors E, et al. Reduction of blood pressure by treatment with alphacalcidol. A double-blind, placebo-controlled study in subjects with impaired glucose tolerance. Acta Med Scand. 1988;223:211-217.
33. Myrup B, Jensen GF, Mc Nair P. Cardiovascular risk factors during estrogen-norethindrone and cholecalcif-erol treatment. Arch Intern Med. 1992;152:2265-2268.
34. Lind L, Wengle B, Wide L, et al. Reduction of blood pressure during long-term treatment with active vitamin D (alphacalcidol) is dependent on plasma rennin activity and calcium status: a double-blind, placebo-controlled study. Am J Hypertens. 1989;2:20-25.
35. Lind L, Hänni A, Lithell H, et al. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am J Hypertens. 1995;8:894-901.
36. Michos ED, Streeten EA, Ryan KA, et al. Serum 25-hydroxyvitamin D levels are not associated with subclinical vascular disease or C-reactive protein in the Old Order Amish. Calcif Tissue Int. 2009;84:195-202.
37. Hathcock JN, Shao A, Vieth R, et al. Risk assessment for vitamin D. Am J Clin Nutr. 2007;85:6-18.
38. Carbone LD, Rosenberg EW, Tolley EA, et al. 25-Hydrox-yvitamin D, cholesterol, and ultraviolet irradiation. Metabolism. 2008;57:741-748.